Becton, Dickinson and Company (BDX) is listed on NYSE and operates in the Medical - Instruments & Supplies industry (Healthcare sector).
Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company's BD Medical segment offers peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular care and preparation products, needle-free IV connectors and extensions sets, closed-system drug transfer devices, hazardous drug detections, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, and sharps disposal systems; IV medication and infusion therapy delivery systems, medication compounding workflow systems, automated medication dispensing and supply management systems, and medication inventory optimization and tracking systems; syringes, pen needles, and other products for diabetes; and prefillable drug delivery systems. Its BD Life Sciences segment provides specimen and blood collection products; automated blood and tuberculosis culturing, molecular testing, microorganism identification and drug susceptibility, and liquid-based cytology systems, as well as rapid diagnostic assays, microbiology laboratory automation products, and plated media products; and fluorescence-activated cell sorters and analyzers, antibodies and kits, reagent systems, and solutions for single-cell gene expression analysis, as well...
| Rating | Analysts |
|---|---|
| Strong Buy | 0 |
| Buy | 16 |
| Hold | 17 |
| Sell | 1 |
| Strong Sell | 0 |
Becton, Dickinson and Company, founded in 1897 and headquartered in Franklin Lakes, New Jersey, operates in the healthcare sector, specifically within the medical instruments and supplies industry. The company develops, manufactures, and sells a wide range of products for healthcare institutions, physicians, life science researchers, clinical laboratories, the pharmaceutical industry, and the general public globally.
The BD Medical segment provides products such as intravenous (IV) catheters, central lines, dialysis catheters, and drug transfer devices. It also offers medication delivery systems, including infusion therapy, automated dispensing, and inventory management systems, as well as diabetes care products and prefillable drug delivery systems.
The BD Life Sciences segment supplies specimen and blood collection products, molecular testing systems, and microbiology laboratory automation products. It also offers cell sorters, analyzers, and reagents for various diagnostic applications.
The BD Interventional segment includes products for hernia repair, surgical infection prevention, and urology, as well as peripheral intervention products. These offerings support a range of medical and surgical procedures.
Over the past three fiscal years, the company has demonstrated a consistent increase in revenue, achieving a compound annual growth rate (CAGR) of 6.2%, rising from $19.37 billion in 2023 to $21.84 billion in 2025. This revenue growth has been accompanied by a modest improvement in profitability, as evidenced by the gross margin expanding by 3.3 percentage points to 45.4% and the operating margin increasing by 0.9 percentage points to 11.8%. However, the net margin remained relatively stable, with a slight increase of 0.02 percentage points, ending at 7.7%. The company's earnings per share (EPS) showed inconsistency, with a CAGR of 8.6%, moving from $4.94 to $5.83, reflecting the impact of operational fluctuations. Cash generation has been robust, with free cash flow (FCF) growing at a CAGR of 12.4%, reaching $2.67 billion in 2025, and the FCF margin improving by 1.3 percentage points to 12.2%. Despite this, net debt increased from $15.34 billion to $18.33 billion, indicating a higher leverage position. The company's capital efficiency improved, as seen in the consistent increase in asset turnover to 0.39 and a decrease in capex intensity to 3.5%, suggesting a more capital-light operational model. Overall, the company has effectively leveraged its revenue growth to enhance profitability and cash generation, although the increase in net debt warrants attention.
Becton, Dickinson and Company (BD) is set to announce its second-quarter fiscal 2026 financial results on May 7, 2026. This announcement will provide insights into the company's performance for the quarter ending March 31, 2026, and will include updates on its operations and strategy. In the realm of product innovation, BD recently unveiled the HemoSphere Stream for continuous noninvasive blood pressure monitoring and rolled out a next-generation medication dispensing system across Europe, highlighting its commitment to advancing healthcare technology. On the analyst front, BD has been identified as a high-quality dividend stock trading at a discount, with shares priced at approximately 12 times forward earnings, compared to peers like Medtronic at 15 times. This valuation suggests potential investment opportunities amid market volatility. Additionally, BD received industry recognition for transparency and resiliency, earning top honors from the Healthcare Industry Resiliency Consortium (HIRC) for the fourth consecutive year. This accolade underscores BD's robust supply chain and customer-centric approach. Lastly, Rick Byrd, Executive Vice President and President of the Interventional Segment, announced his retirement after nearly 25 years with the company, marking a significant leadership transition. These developments collectively paint a picture of a company focused on strategic growth, innovation, and maintaining strong industry partnerships.